Tvardi Therapeutics is trading $1.05, up 8.36%, with no fresh catalyst identified.
- No company-specific announcement dated October 23, 2026, surfaced in reviewed news or release listings.
- Latest identified release: October 14, about a conference appearance; conference coverage and a Chardan buy-rating report appeared October 20, neither establishing a fresh catalyst.
- Negative supplied market context does not clearly explain the gain. No live volume figure was provided; external trading data was not used for price calculations.